2018
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions
Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 102-109. PMID: 28991888, PMCID: PMC5720915, DOI: 10.1097/qai.0000000000001562.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS Dementia ComplexAIDS-Related Opportunistic InfectionsAlkynesAmericasAtazanavir SulfateBenzoxazinesCohort StudiesCyclopropanesDarunavirEuropeFemaleHIV Protease InhibitorsHumansLeukoencephalopathy, Progressive MultifocalLopinavirMaleMeningitis, CryptococcalMiddle AgedProspective StudiesReverse Transcriptase InhibitorsToxoplasmosisConceptsNucleoside reverse transcriptase inhibitor (NRTI) backboneReverse transcriptase inhibitor backboneHazard ratioNeurological conditionsInhibitor backbonePooled logistic modelCombined end pointRespective hazard ratiosProgressive multifocal leukoencephalopathyProspective cohort studyAntiretroviral therapy regimensHIV-positive individualsHIV-CAUSAL CollaborationIncidence of AIDSCART initiationHIV dementiaAntiretroviral therapyCART regimenCryptococcal meningitisMultifocal leukoencephalopathyClinical characteristicsCohort studyTherapy regimensAtazanavirLopinavir
2017
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection
Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology And Drug Safety 2017, 26: 1172-1181. PMID: 28722244, PMCID: PMC5624832, DOI: 10.1002/pds.4258.Peer-Reviewed Original ResearchConceptsHepatitis C virusHIV/HCV patientsHuman immunodeficiency virusHepatic decompensationAntiretroviral therapyHCV patientsCohort studyHazard ratioHIV/hepatitis C virus (HCV) coinfectionChronic hepatitis C virusHepatitis C virus coinfectionHIV/HCV coinfectionHIV-/HCV-coinfected patientsVeterans Aging Cohort StudyC virus coinfectionChronic hepatic injuryAging Cohort StudyRisk of deathToxic nucleoside analoguesMarginal structural modelsHCV coinfectionLiver decompensationART regimensDecompensation eventsHepatic injury
2016
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine 2016, 95: e5133. PMID: 27741139, PMCID: PMC5072966, DOI: 10.1097/md.0000000000005133.Peer-Reviewed Original ResearchConceptsCD4 cell countEfavirenz regimenVirologic failureVirologic outcomesSurvival differencesNucleoside reverse transcriptase inhibitor (NRTI) backboneCell countReverse transcriptase inhibitor backboneAtazanavir-containing regimensAIDS-free survivalHuman immunodeficiency virusImmune deficiency syndromeHIV-CAUSAL CollaborationAtazanavir regimenHazard ratioClinical outcomesImmunodeficiency virusProspective studyDeficiency syndromeMean changeRegimensEfavirenzTime-varying covariatesInhibitor backboneRegimen
2012
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS 2012, 26: 1691-1705. PMID: 22546987, PMCID: PMC3647467, DOI: 10.1097/qad.0b013e328354f497.Peer-Reviewed Original ResearchConceptsAIDS-free individualsCD4 cell countEfavirenz regimensVirologic failureVirologic outcomesCell countMore nucleoside reverseNevirapine-containing regimensTreat hazard ratiosTypes of regimensProspective observational studyHIV-CAUSAL CollaborationEffect of efavirenzEfavirenz regimenNevirapine regimenNevirapine regimensHazard ratioNucleoside reverseClinical outcomesProspective studyInverse probability weightingLower incidenceObservational studyRegimensLower mortality
2008
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Mugavero M, May M, Harris R, Saag M, Costagliola D, Egger M, Phillips A, Günthard H, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill M, Justice A, D'Arminio Monforte A, Lampe F, Miró J, Staszewski S, Sterne J. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS 2008, 22: 2481-2492. PMID: 19005271, PMCID: PMC2793403, DOI: 10.1097/qad.0b013e328318f130.Peer-Reviewed Original ResearchConceptsAntiretroviral-naïve patientsAntiretroviral therapyLopinavir/ritonavirVirologic failureClinical eventsThird drugART initiationCohort studyAntiretroviral Therapy Cohort CollaborationNaïve HIV-positive patientsHIV-positive patientsObservational cohort studyHIV Cohort StudyART regimenCohort CollaborationNaïve patientsClinical outcomesResidual confoundingClinical practicePatientsInhibitor backboneAbacavirNevirapineTherapyDrugs
2007
Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies
Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007, 21: 1579-1589. PMID: 17630553, PMCID: PMC3460378, DOI: 10.1097/qad.0b013e3281532b31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesCD4 Lymphocyte CountCohort StudiesCyclopropanesDrug Administration ScheduleFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedPatient ComplianceReverse Transcriptase InhibitorsRNA, ViralTreatment OutcomeVeteransViral LoadConceptsPrevious antiretroviral exposureSingle PI regimensCombination ARTImmunological outcomesAntiretroviral exposureHIV RNAPI regimensProtease inhibitorsCombination antiretroviral therapy regimenHIV-RNA viral suppressionTreatment assignmentVeterans Affairs Healthcare SystemEfavirenz-based regimenGreater adherence levelsLog HIV RNAAntiretroviral therapy regimenBaseline clinical characteristicsCD4 cell countCombination antiretroviral therapyPharmacy refill recordsOutcome one yearAntiretroviral prescriptionsAntiretroviral regimensEfavirenz regimensNevirapine regimens
2004
Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy
Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 37: 1147-1154. PMID: 15319674, DOI: 10.1097/01.qai.0000136738.24090.d0.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCopies/mLBaseline HIV-1 RNA levelsNew AIDSCopies/Moderate viremiaRNA levelsPlasma HIV-1 RNAAIDS-defining diagnosisAntiretroviral therapy historyActive antiretroviral therapyUnited States cohortHIV-1 RNACells/Proportional hazards modelCD4 count changesImmunologic deteriorationAntiretroviral therapyCD4 countPrior AIDSUndetectable viremiaViral suppressionImmunologic statusHIV infectionClinical benefitPredictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. The Lancet 2004, 364: 51-62. PMID: 15234856, DOI: 10.1016/s0140-6736(04)16589-6.Peer-Reviewed Original ResearchConceptsProportional hazards modelVirological failureCD4 cell count slopesHIV-1 RNA concentrationsCox proportional hazards modelCD4 cell countPredictors of deathAntiretroviral therapyHIV cohortDual therapyClinical outcomesViral loadHIV replicationDrug classesTreatment strategiesTreatment informationPatientsDemographic characteristicsRNA concentrationRegression analysisTherapyFailureCohortDisease progression in HIV-infected patients treated with stavudine vs. zidovudine
Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM, Team T. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine. Journal Of Clinical Epidemiology 2004, 57: 89-97. PMID: 15019015, DOI: 10.1016/s0895-4356(03)00245-2.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDatabases, FactualDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHIV InfectionsHIV Wasting SyndromeHumansProportional Hazards ModelsProspective StudiesReverse Transcriptase InhibitorsStavudineZidovudineConceptsCells/microLDisease progressionLandmark analysisCox proportional hazards modelEvent-free survivalHIV-1 patientsHIV-1 RNAProportional hazards modelPrevious AIDSStavudine treatmentCD4 countHIV infectionInhibitor useCombination therapyUnadjusted analysesObservational studyHIV-1U.S. cohortHazards modelPatientsZidovudineStavudineNew casesNRTIsProgression